Switching treatment for neovascular age-related macular degeneration from bevacizumab to ranibizumab who is likely to benefit from the switch?

Elad Moisseiev*, Gabriel Katz, Joseph Moisseiev, Anat Loewenstein, Michaella Goldstein, Yosef Lomnicky, Yitzhak Abend, Giora Treister, Dafna Goldenberg, Hana Levkovitch-Verbin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Switching treatment for neovascular age-related macular degeneration from bevacizumab to ranibizumab who is likely to benefit from the switch?'. Together they form a unique fingerprint.

Keyphrases

Neuroscience